Zerlasiran siRNA Drug Lowers Lp(a) by 90% in Phase 2 Results ...Middle East

Silence Therapeutics has announced positive topline 36-week data from its ongoing phase 2 study of zerlasiran, a long-acting agent directed at lowering Lp(a) levels. Medscape Medical News

Hence then, the article about zerlasiran sirna drug lowers lp a by 90 in phase 2 results was published today ( Thursday 14/03/2024 - 12:29 PM ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Zerlasiran siRNA Drug Lowers Lp(a) by 90% in Phase 2 Results )

Also on site :

• No Doubt Transport Las Vegas Sphere to Orange County for New Residency: See Their Full Night 1 Setlist
• Quote of the Day: Trisha Yearwood Shares Her Secret to Self-Love
• German ban on Soviet WWII symbols is ‘discrimination’ – former MEP (VIDEO)